Affiliation:
1. SULEYMAN DEMIREL UNIVERSITY
Abstract
The Copper-64 radioisotope, whose academic research continues on diagnostic and therapeutic use, was examined in this study. 64Cu radioisotope is unique among other Cu isotopes for medical usage due to its low positron energy, appropriate half-life, and short tissue penetration. In cases where experimental data are missing, cross-section calculations can be used, and the existence of the cross-section data may provide various advantages in managing time, cost, and efficiency. In this context, investigated detailed cross-section calculations of the 64Cu isotope. To this end, cross-sections acquired from various calculation codes were compared with the literature, and alternative production routes were investigated. Using the nuclear reaction codes TALYS and EMPIRE, cross-section data of the 64Cu isotope were obtained from the 64Ni(p,n)64Cu, 65Cu(p,n+p)64Cu, 68Zn(p,n+α)64Cu, 65Cu(n,2n)64Cu, 64Ni(d,2n)64Cu, and 63Cu(d,p)64Cu reactions with the equilibrium and pre-equilibrium models. The results were compared with the available literature data from the EXFOR database.
Reference46 articles.
1. [1] IAEA (International Atomic Energy Agency), IAEA Radioisotopes and Radiopharmaceuticals Reports No. 1; Cyclotron Produced Radionuclides: Emerging Positron Emitters for Medical Applications: 64Cu and 124I, https:// https://www.iaea.org/publications/10791/cyclotron-produced-radionuclides-emerging-positron-emitters-for-medical-applications-64cu-and-124i Retrieved April 4, 2022.
2. [2] IAEA (International Atomic Energy Agency), Cyclotron Produced Radionuclides: Principles and Practice, Technical Reports Series No. 465, https://www-pub.iaea.org/MTCD/publications/PDF/trs465_web.pdf. Retrieved March 21, 2022.
3. [3] Gutfilen B., Souza S. A., Valentini G., Copper-64: A Real Theranostic Agent, Drug Des. Devel. Ther., 12 (2018) 3235–3245.
4. [4] Boschi A., Martini P., Janevik-Ivanovska E., Duatti A., The Emerging Role of Copper-64 Radiopharmaceuticals as Cancer Theranostics, Drug Disc. Today, 23(8) (2018) 1489–1501.
5. [5] Capriotti G., Piccardo A., Giovannelli E., Signore A., Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent, J Clin Med, 12(1) (2022) 223.